BackRhythm Pharmaceuticals Overview

Rhythm Pharmaceuticals Selling, General & Admin

Rhythm Pharmaceuticals selling, general & admin — quarterly history, peer benchmarks, and growth trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly SG&A Expenses

$63.59M
62.69% YoY

As of Mar 31, 2026

Annual SG&A Expenses (TTM)

$219.44M
47.27% YoY

Trailing 12 months ending Mar 31, 2026

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Rhythm Pharmaceuticals (RYTM) FAQ

Stockcircle tracks selling, general & admin for Rhythm Pharmaceuticals (RYTM), including historical charts and peer comparisons when data is available. Check back as new filings are published, or open the stock overview for a broader fundamental snapshot.

This Selling, General & Admin page is built for Rhythm Pharmaceuticals's historical SG&A expenses trend and peer context. When enough reporting periods are on file, the charts below visualize how the metric has moved over time.

Use SG&A expenses as one input alongside growth, profitability, valuation, and ownership activity. Stockcircle links related metric pages and the main RYTM overview so you can move from this figure to the surrounding analysis quickly.